Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 May 8.
Published in final edited form as: Nanoscale. 2022 Mar 17;14(11):4065–4072. doi: 10.1039/d1nr07551a

The use of advanced spectral imaging to reveal nanoparticle identity in biological samples

Qamar A Alshammari a,b,, Rajasekharreddy Pala a,, Ayan K Barui a, Saud O Alshammari a,c, Andromeda M Nauli d, Nir Katzir e, Ashraf M Mohieldin a, Surya M Nauli a,f
PMCID: PMC9080669  NIHMSID: NIHMS1799957  PMID: 35230362

Abstract

Nanoparticles (NPs) have been used in drug delivery therapies, medical diagnostic strategies, and as current Covid-19 vaccine carriers. Many microscope-based imaging systems have been introduced to facilitate detection and visualization of NPs. Unfortunately, none can differentiate the core and the shell of NPs. Spectral imaging has been used to distinguish a drug molecule and its metabolite. We have recently integrated this technology to a resolution of 9 nm by using artificial intelligence-driven analyses. Such a resolution allowed us to collect many robust datapoints for each pixel of an image. Our analyses could recognize 45 spectral points within a pixel to detect unlabeled Ag-NPs and Au-NPs in single live cells and tissues (liver, heart, spleen and kidneys). The improved resolution and software provided a more specific fingerprinting for each single molecule, allowing simultaneous analyses of 990 complex interactions from the 45 points for each molecule within a pixel of an image. This in turn allowed us to detect surface-functionalization of Ag-NPs to distinguish the core from the shell of Ag-NPs for the first time. Our studies were validated using various laborious and time-consuming conventional techniques. We propose that spectral imaging has tremendous potential to study NP localization and identification in biological samples at a high temporal and spatial resolution, based primarily on spectral identity information.

Introduction

Conventional methods used for the quantification of inorganic NPs include inductively-coupled plasma mass spectrometry (ICP-MS) and inductively-coupled plasma atomic emission spectroscopy (ICP-AES).13 In addition to the matrix interference, some disadvantages in ICP-associated methods include chemical interference, the necessity of liquidized samples, low plasma sensitivity to organic solvents, and ineffectiveness of the nebulizer. To overcome these drawbacks, non-destructive techniques have also been developed. These include the use of fluorescent-labeled NPs4,5 and the modern ultrasonic holography.6,7

While fluorescent-conjugated NPs are generally used to identify NP localization in live biological samples, such conjugation could interfere with NP function, localization, cytotoxicity and biodistribution.810 Thus, different imaging modalities have been recently introduced to image unlabeled-NPs without destroying biological tissues. Based on the light-refractive index of NPs, NP detection in live cells has been performed.11 The specific scattered-light of NPs allows real-time monitoring of unlabeled NPs.12 In addition to Raman spectroscopy,13 standard optical spectroscopic microscopy has also been used to image NPs, albeit this was done at a much narrower scanning range of 200 nm.14 Different optical microscopy techniques, used to detect a specific spectrum for NPs, have therefore been proposed to capture absorption spectra15 and the plasmon resonance scattering or extinction spectra of various NPs.1619

Despite recent advances in optical microscopes, visualizing unlabeled-NPs remains a challenge. This is primarily due to intensity-based measurements performed at a very narrow spectrum optimized for different studies and systems at different laboratories. We recently introduced a spectral imaging system in which broader spectral characteristics are first identified, characterized and stored in a library.20 Unlike other previous studies, however, our current studies did not identify a molecule based merely on the spectral intensity, relative intensity, or spectral points. Our new strategies using a higher spectral resolution and artificial intelligence for point recognition improved our capability to differentiate two very similar molecules.

Results

We can now scan absorbance spectra from 400 nm to 800 nm with a resolution of 9 nm (ESI Fig. 1). This improved spectral imaging provides much more detailed information for a more accurate image analysis, resulting in 45 unique spectral points for each pixel. These points are interconnected resulting in 990 unique interactions (ESI Fig. 2). Using artificial intelligence-driven analysis to recognize relative interactions between 2 points, the integrations of such interactions provide unique fingerprints for different chemicals. The key feature is that we could recall all these specific interactions from the library fairly quickly. These relative interaction points become the unique identity (or fingerprint) of a molecule.

We report here that spectral imaging can provide a high temporal and spatial resolution of silver nanoparticles with a shell (Ag(s)-NPs) or without a shell (Ag-NPs). Our validation results on gold nanoparticles (Au-NPs) are located mainly in the supplementary information. These NPs were characterized for their syntheses, hydrodynamic sizes and structural compositions (ESI Fig. 3; see Method).

Spectral signatures of Ag(s)-NPs and Ag-NPs were identified with a major peak at 420 nm

Using a microscope equipped with hyperspectral imaging (GenASIs from Applied Spectral Imaging), we imaged and recorded the spectral characteristics of the clusters of Ag(s)-NPs before and after incubation with cells (Fig. 1a). We captured the spectral range between 400 and 800 nm for Ag(s) NPs in the presence and absence of cells. Ag(s)-NPs had characteristic spectra with a distinctive peak at 420 nm (Fig. 1b). This peak was consistent with a previous study.21 While this peak was the main characteristic of Ag(s)-NPs, we also looked at different features that could contribute to the characteristics of Ag(s)-NPs. Interestingly, we could generate two distinct libraries for Ag(s)-NPs. The peak of Ag(s)-NPs could be distinctively differentiated by an additional “shoulder” that only appeared at the peripheral or shell of the NPs. Of note, silver–polymer core–shell NPs are generally known for their unique optical properties, in which the shell of Ag also plays a critical role in protecting the Ag core.22,23 A shift in the shoulder peak could therefore be used to differentiate the core and shell of Ag-NP clusters. We quantified the spectral intensities of these peaks before and after 18-hour incubation with cells (Fig. 1c). As verified by traditional spectrophotometry, the linearity of Ag(s)-NPs was observed with a peak at 420 nm (ESI Fig. 4a), indicating that we could predict the singularity or number of NPs in each pixel of an image based on the peak intensity of the spectra. Extrapolating from these intensity differences, our data suggested that Ag(s)-NPs tended to aggregate more in solution than in cells (Fig. 1d).

Fig. 1.

Fig. 1

Identification of the spectra of Ag(s)-NPs. (a) Brightfield images of the Ag(s)-NPs in the cell-free system (positive control), fixed cells (negative control), and 16-hour Ag(s)-NPs-treated cells (Ag(s)-NPs). The spectral images were extracted from the spectra library for the Ag(s)-NPs. Merged images illustrate superimposed brightfield and spectral images. The pink spectral image exhibits the core area of the Ag(s)-NP cluster, while the yellow color represents the shell region. (b) The graphs illustrate the wavelength peaks at ~420 nm for the positive control and the incubated cells. The pink wavelength displays the intensity of the core area and the yellow wavelength shows the shell part (with a small shoulder; insert and arrow). The black color exhibits the spectrum of the background area. The negative control spectra were identified based on unmatched spectra from our libraries. (c) The bar graphs show the variation of intensity data points at 420 nm. (d) The signal intensities were compared among cell-free positive control, non-treated cells negative control, and Ag(s)-NPs-treated cells. N = 4–5 for each positive and negative controls; N = 8 for experimental groups. ****, P < 0.0001.

To confirm our observation of Ag(s)-NPs, we synthesized Ag-NPs exclusively without the shell. The spectral characteristics of the Ag-NPs before and after incubation with cells were recorded (ESI Fig. 5a). The Ag-NPs have the same characteristic spectra of Ag(s)-NPs, at ~420 nm, except that Ag-NP spectra were revealed without the additional “shoulder” (ESI Fig. 5b). We also calculated the spectral intensities of these peaks before and after 18-hour incubation with cells (ESI Fig. 5c). This revealed the specificity of spectral imaging to differentiate between the spectral characteristics of different types of silver NPs (Ag-NPs and Ag(s)-NPs).

Spectral signature of Au-NPs was identified with a major peak at 552 nm

Another inorganic NP was prepared to further confirm the capabilities of spectral imaging to identify a different NP, Au-NPs (ESI Fig. 6a). Capturing spectra between 400 and 800 nm revealed that the Au-NPs had a unique spectral peak located between 520 and 580 nm (ESI Fig. 6b), consistent with a previous study.24 Background spectra without or with cells were captured to differentiate the spectral intensity of a peak at 552 nm (ESI Fig. 6c). The specific subcellular localization of Au-NPs in the cells could be determined by examining the spectral characteristics of each pixel in the image. In the fixed cells, after treatment with Au-NPs for 18 hours, we could detect individuals or clusters of Au-NPs. To independently verify the microscopy spectra, we examined the spectra of Au-NPs using traditional spectrophotometry (ESI Fig. 4b). The linearity of Au-NPs was observed with a peak at 536 nm, indicating that we could predict the singularity or number of NPs in each pixel of an image based on the peak intensity of the spectra. Extrapolating from these data, our studies suggested that Au-NPs tended to disperse more readily in cells than in solution (ESI Fig. 6d).

Spectral imaging showed dynamic Ag(s)-NP or Au-NP accumulation in the cell nucleus

Once the spectral signatures for both Ag(s)-NPs and Au-NPs were identified and defined in the libraries, analytical software was used to perform spectral identity for each pixel of an image in order to identify pixels with the spectral resemblance of Ag(s)-NPs or Au-NPs. Background spectral characteristics could be taken from the non-treated cells (negative control) or different areas within the field of view in the image (see Method). This was a powerful method to trace non-fluorescence inorganic substances. We thus applied this technique to the time-lapse imaging of cells treated with 0.1 mg Ag(s)-NPs in 2 mL cell media (Fig. 2a; ESI Fig. 7). We observed the continuous accumulation of Ag(s)-NPs in the cells. Our libraries could distinctively differentiate the core (pink color) and shell (yellow color) clusters of Ag(s)-NPs. Once the pixel identity of Ag(s)-NP signature spectra was established, we randomly selected a pixel to study individual spectra after background subtraction (Fig. 2b; ESI Fig. 8). We quantified spectra representing NPs in the cytoplasm or nucleus within single cells (Fig. 2c). It was apparent that our Ag(s)-NPs were dynamically moving in and out of the cells, as depicted in the fluctuation of total NPs in a single cell. The NPs were also moving in and out of the cell nucleus, as shown by the number of NPs in the nucleus at each time point. In this particular study, cells were also moving in or out from our field of view. More Ag(s)-NPs would eventually accumulate in the cells. Ag(s)-NPs would subsequently accumulate in the cell nucleus (ESI Fig. 7 and 8).

Fig. 2.

Fig. 2

Time-lapse imaging of Ag(s)-NPs. (a) Sequential time imaging of cells treated with 0.1 mg of Ag(s)-NPs in 2 mL media was captured for about 8 hours. Brightfield images and spectral scans were taken every 20 minutes (ESI Fig. 4). (b) Spectral analysis was performed at the end of 8 hours after subtraction from the background spectra (ESI Fig. 5). The Ag(s)-NP libraries differentiated the core and shell of NP clusters. The pink wavelength displays the intensity of the core area and the yellow wavelength shows the shell part (with a small shoulder; insert and arrow). (c) Line graphs illustrate the time-lapse analysis from 5 independent experiments. A number of Ag(s)-NPs (#NPs) was measured in one cell at each time point. Total #NPs were calculated from the localization of NPs in the cytoplasm (outside the nucleus) and nucleoplasm (inside the nucleus) within a cell. Comparisons were made at the beginning (1 min) and end (460 min) of the 8-hour experiments. N = 5. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

We next studied time-lapse imaging of Au-NPs in single living cells (ESI Fig. 9a and 10). We noted the continuous accumulation of Au-NPs in the cells. Once the pixel resembling the Au-NP spectral signature was identified, we randomly selected a pixel to study individual spectra after background subtraction (ESI Fig. 9b and 10). Through the time-lapse imaging to detect the movements of Au-NPs, we could quantify potential NPs in the cytoplasm or nucleus within single cells (ESI Fig. 9c). It was apparent that Au-NPs were dynamically moving in and out of the cells, as indicated by the fluctuation in total NPs in a single cell at a single time point. Similarly, NPs were in and out of the cell nucleus as depicted by the number of NPs in the nucleus at each time point. As time passed, more NPs accumulated in the cells, but this accumulation was started from the cytoplasm and followed by the nucleus. It was evident that Au-NPs preferentially localized in the cell nucleus (ESI Fig. 10 and 11). While both Au-NPs and Ag(s)-NPs are largely known to localize in the nucleus,25,26 we showed for the first time the dynamic movements of Au-NPs and Ag-NPs in the cytosol and nucleus (ESI Fig. 7 and 10).

Electron microscopy and silver staining were used to verify the spectral imaging approach

To verify our subcellular localization findings of NPs in time-lapse imaging studies, we performed transmission electron microscopy (TEM) and silver staining analyses. TEM captured images of the cells treated with Ag(s)-NPs, Ag-NPs, and Au-NPs for 16 hours (Fig. 3a; ESI Fig. 12a). While we were not able to capture the dynamics of these NPs due to sample fixation, the TEM studies confirmed the accumulation of NPs in the cell nucleus. Likewise, the localization of NPs was confirmed to be mostly in the nucleus of cells using silver staining to generate dark-brown contrast in phase images (Fig. 3b; ESI Fig. 12b). Because the contrast was primarily enhanced by metallic silver attached at the periphery of the NPs, the spectral signatures within the NPs were not much altered (Fig. 3c; ESI Fig. 12c).

Fig. 3.

Fig. 3

TEM analysis and silver staining of Ag(s)-NPs and Ag-NPs. (a) TEM analyses were performed after treatment of Ag(s)-NPs or Ag-NPs for 16 hours. An embossing filter was applied in some regions of the cell nucleus for improving clarity of the NPs present (insert with arrows). (b) Cells after silver staining show brightfield images of the Ag(s)-NP and Ag-NP treated cells for 16 hours. The spectral images were extracted and pseudo-colored for the Ag(s)/Ag-NPs. Merged images revealed superimposed brightfield and spectral images to show the location of Ag(s)/Ag-NPs in the cell nucleus. The pink pseudocolor shows the core area of the Ag(s)/Ag-NPs, while the yellow color represents the shell region of Ag(s)-NPs. (c) The spectral graphs clarifying the wavelength peaks of Ag(s)/Ag-NPs at ~420 nm. The pink wavelength exhibits the intensity of the core area and the yellow wavelength displays the shell region. The black color shows the spectrum of the background area. N = 5.

Verification of the spectral imaging approach was performed in vivo using ICP-MS

We next assessed the practicality of spectral imaging to study the distribution of the NPs within mouse organ tissues. Remarkably, we found distribution of the Ag(s)-NPs, Ag-NPs and Au-NPs in the kidney, spleen, liver and heart tissues (Fig. 4a, ESI Fig. 13 and 14). Importantly, the spectral characteristics of the core and shells of Ag(s)-NPs were not altered (Fig. 4b and c). Based on our quantitative analyses, we showed that Ag(s)-NPs and Ag-NPs were distributed widely in the kidney and spleen, respectively (Fig. 5a). On the other hand, Au-NPs were in the liver (ESI Fig. 15a). As a validation of NP distribution within the organs, we conducted ICP-MS analyses. Of note, the ICP-MS method and its standard curve did not differentiate between Ag(s)-NPs and Ag-NPs (ESI Fig. 15b). We performed separate analyses of those tissues for Ag(s)-NPs, Ag-NPs or Au-NPs (Fig. 5b, ESI Fig. 15c). We next examined the correlation analyses of the NP distribution. We found a significant correlation in the distributions of Ag(s)-NPs and Ag-NPs in spectral imaging and ICP-MS among the tissues (Fig. 5c). Likewise, a similar correlation was observed in Au-NPs (ESI Fig. 15d), indicating a consistency between the spectral imaging and the ICP-MS approaches.

Fig. 4.

Fig. 4

Distribution of Ag(s)-NPs in animal tissues. (a) Brightfield images of the Ag(s)-NPs in different organ tissues (liver, heart, spleen, and kidneys) after intravenous injection with Ag(s)-NPs for 24 hours. The spectral images were extracted from the spectral libraries for Ag(s)-NPs. Merged images display combined brightfield and spectral images. (b) The pink pseudo-colored images show the core area of the Ag(s)-NPs, while the yellow color shows the shell region. (c) The graphs reveal the wavelength characteristics of the Ag(s)-NP cluster at ~420 nm. The pink wavelength exhibits the intensity of the core area and the yellow wavelength displays the shell part. The background is shown as a black colored wavelength. N = 5.

Fig. 5.

Fig. 5

Correlation analysis of Ag(s)-NP and Ag-NP distributions in the tissues using spectral imaging and ICP-MS. The bar graphs exhibit the distributions of Ag(s)-NPs and Ag-NPs in the liver, heart, spleen, kidneys, which were obtained using spectral imaging (a) or ICP-MS (b). (c) The correlation analysis of the distribution of Ag(s)-NPs and Ag-NPs in different organs between ICP-MS and spectral imaging is shown. N = 5 for each group and organs.

Discussion

The significance of the use of spectral imaging in our studies are as follows. First, we were able to identify and quantify the presence of NPs without the need to destroy or liquify the samples. This allowed us to perform live-cell imaging that was otherwise not possible. Second, we could calibrate the spectral library by using both imaging and the singularity/plurality of the spectral “signature” of a chemical. In Ag(s)-NPs, for example, we could observe the plurality of spectra at 420 nm, i.e. a peak with or without a shoulder. Looking at the images, we showed that the peaks without a shoulder were always at the center of NPs, whereas the peaks with a shoulder were localized at the periphery. Third, we did not need to fluorescently label our NPs. Labeling NPs required an additional step in the synthesis process, making the process more expensive and laborious. Labeled NPs could also alter the molecular functions and characteristics of NPs.810 Fourth, spectral imaging was also applicable to fluorescent or auto-fluorescent molecules. Using spectral imaging, we were able to visualize fluorescent molecules fairly easily based mainly on their predominant fluorescence spectra (data not shown).20 Note that the spectral identities might be different between non-labeled and fluorescent-labeled NPs. A fluorescence microscope might be more practical to detect the fluorescent-labeled NPs. Fifth, the spectral imaging approach was a simple yet inexpensive method for unlabeled NPs, the resolution of which depends on the quality of the lens and camera from standard optical microscopes. Unlike laser-based microscopic devices, such as in Raman spectroscopy, spectral imaging systems could be installed on upright or inverted microscopes that are readily available in many research laboratories.

Using spectral imaging, we were able to observe the dynamic uptake, movement, and distribution of different types of free-labeled NPs in a single cell. Conducting the live imaging technique while scanning the spectra from 400 to 800 nm, we were able to explore the behaviors of the NPs in a single cell, in which the NPs eventually accumulate in the cell nucleus. The spectral imaging was validated by both TEM and silver staining studies, although TEM and silver staining techniques did not provide the live-dynamics nature of NPs due to the requirement for cell fixation. In addition, we were able to study the distribution of NPs among tissues using spectral imaging. We found that Ag(s)-NPs and Ag-NPs were primarily localized in the kidneys and spleen, respectively. On the other hand, Au-NPs were distributed primarily in the liver. Of note, these tissues could be easily visualized with standard H&E staining, allowing easier sample preparation relative to an ICP-MS approach. It is known that larger nanoparticles (>6 nm) are cleared from the blood by the reticuloendothelial system. They accumulate in the liver and spleen; they are also captured by the mononuclear phagocyte system, which can be eliminated by the hepatobiliary system or may remain in the body for a long time.2729 However, it has been reported that the highest concentration of Ag-NPs is initially found in the liver, and over time the highest concentration of Ag-NPs should be found in the spleen.30 Importantly, the spectral imaging was confirmed by the conventional ICP-MS technique with respect to tissue distribution analyses.

A few label-free methods have been developed for observing NPs in live cells. For example, transitory absorption microscopy has been utilized to capture carbon nanotubes in cells, and scatter-enhanced phase-contrast microscopy has been utilized to assess the intracellular behavior of unlabeled silicon nanowires.15,31 Other approaches, such as hyperspectral stimulated Raman scattering microscopy,13 optical diffraction tomography,11 and dark-field microscopy,32 have been utilized to investigate unlabeled NPs inside cells. However, using current technology to track unlabeled NPs in live cells in real-time with reliable spatial resolution remains a challenge. Besides, it is necessary to monitor both NPs and biomolecules to fully comprehend the interaction between NPs and cells/tissues. To the best of our knowledge, no technique has utilized a broader band of spectra in the range of 400–800 nm for real-time imaging of label-free NPs. A broader spectrum is required to extract more precise characteristics of a single molecule.20 Specifically, this approach provides a more specific fingerprinting for each NP.

In summary, the combination of spectroscopy and imaging provides high-resolution spatial and temporal information of spectral characteristics in each pixel. This approach could serve as a valuable technique to understand the distribution, dynamic movement, and behavior of nanoparticles used in biomedical research and clinical medicine.

Conclusions

Spectral imaging provides both intensity and spectral information for each pixel of an image. We have achieved spectral resolution to 9 nm between 400 and 800 nm, resulting in 45 unique datapoints for each spectrum in each pixel. We have also integrated our image and spectral analyses by using artificial intelligence to recognize the datapoints by interconnecting each point to provide unique information of chemical fingerprints. This strategy allows differentiation between the core and the shell of silver-nanoparticles (Ag-NPs) for the first time. The advances of spectral imaging resolution and analysis also allow us to detect the dynamics of NP distribution and tracking/identifying NPs and their subcellular localizations in single living cells. Without labeling the NPs and destroying the samples, the advanced spectral microscopy technique allows analyzing NPs in fixed cells, living cells and tissue samples in vivo.

Supplementary Material

1

Acknowledgements

This work was supported in part by the NIH HL131577 and HL131577-S1. The authors acknowledge the use of facilities and instrumentation at the UC Irvine Materials Research Institute (IMRI), which is supported in part by the National Science Foundation through the UC Irvine Materials Research Science and Engineering Center (DMR-2011967). The completion of this work by QAA partially fulfilled the requirements for her Ph.D. degree program in Biomedical and Pharmaceutical Sciences. At Chapman University, A. Sharma provided advice on the imaging validations, F. Amirrad assisted QAA in supervising the tissue processing training, and M. Takahashi and D. Larin-Henriquez were involved in mouse maintenance, reagent preparations and ordering. Li Xing at IMRI assisted in TEM studies.

Footnotes

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Chapman University. The Institutional Animal Care and Use Committee at Chapman University approved our animal studies, and our animal facility was approved by the Office of Laboratory Animal Welfare (OLAW). The OLAW assurance number is D17-00960.

Conflicts of interest

There are no conflicts of interest to declare.

References

  • 1.Antonio DC, Cascio C, Gilliland D, Nogueira AJ, Rossi F and Calzolai L, Biointerphases, 2016, 11, 04B309. [DOI] [PubMed] [Google Scholar]
  • 2.Vanhecke D, Rodriguez-Lorenzo L, Clift MJ, Blank F, Petri-Fink A and Rothen-Rutishauser B, Nanomedicine, 2014, 9, 1885–1900. [DOI] [PubMed] [Google Scholar]
  • 3.Lee S, Bi X, Reed RB, Ranville JF, Herckes P and Westerhoff P, Environ. Sci. Technol, 2014, 48, 10291–10300. [DOI] [PubMed] [Google Scholar]
  • 4.Pala R, Mohieldin AM, Sherpa RT, Kathem SH, Shamloo K, Luan Z, Zhou J, Zheng JG, Ahsan A and Nauli SM, ACS Nano, 2019, 13, 3555–3572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Pala R, Mohieldin AM, Shamloo K, Sherpa RT, Kathem SH, Zhou J, Luan Z, Zheng JG, Ahsan A and Nauli SM, Nano Lett., 2019, 19, 904–914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shekhawat GS and Dravid VP, Science, 2005, 310, 89–92. [DOI] [PubMed] [Google Scholar]
  • 7.Tetard L, Passian A, Venmar KT, Lynch RM, Voy BH, Shekhawat G, Dravid VP and Thundat T, Nat. Nanotechnol, 2008, 3, 501–505. [DOI] [PubMed] [Google Scholar]
  • 8.Snipstad S, Hak S, Baghirov H, Sulheim E, Morch Y, Lelu S, von Haartman E, Back M, Nilsson KPR, Klymchenko AS, de Lange Davies C and Aslund AKO, Cytometry, Part A, 2017, 91, 760–766. [DOI] [PubMed] [Google Scholar]
  • 9.Tenuta T, Monopoli MP, Kim J, Salvati A, Dawson KA, Sandin P and Lynch I, PLoS One, 2011, 6, e25556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F and Tasciotti E, Nanomedicine, 2016, 11, 81–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kim D, Oh N, Kim K, Lee S, Pack CG, Park JH and Park Y, Methods, 2018, 136, 160–167. [DOI] [PubMed] [Google Scholar]
  • 12.Wang F, Chen B, Yan B, Yin Y, Hu L, Liang Y, Song M and Jiang G, J. Am. Chem. Soc, 2019, 141, 14043–14047. [DOI] [PubMed] [Google Scholar]
  • 13.Huang B, Yan S, Xiao L, Ji R, Yang L, Miao AJ and Wang P, Small, 2018, 14, 1–10. [DOI] [PubMed] [Google Scholar]
  • 14.Spicer GLC, Almassalha L, Martinez IA, Ellis R, Chandler JE, Gladstein S, Zhang D, Nguyen TQ, Feder S, Subramanian H, de la Rica R, Thompson SA and Backman V, Nanoscale, 2018, 10, 19125–19130. [DOI] [PubMed] [Google Scholar]
  • 15.Zimmerman JF, Parameswaran R, Murray G, Wang Y, Burke M and Tian B, Sci. Adv, 2016, 2, e1601039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen LQ, Fang L, Ling J, Ding CZ, Kang B and Huang CZ, Chem. Res. Toxicol, 2015, 28, 501–509. [DOI] [PubMed] [Google Scholar]
  • 17.Patskovsky S, Bergeron E, Rioux D and Meunier M, J. Biophotonics, 2015, 8, 401–407. [DOI] [PubMed] [Google Scholar]
  • 18.Chen LQ, Xiao SJ, Peng L, Wu T, Ling J, Li YF and Huang CZ, J. Phys. Chem. B, 2010, 114, 3655–3659. [DOI] [PubMed] [Google Scholar]
  • 19.Ling J, Li YF and Huang CZ, Anal. Chem, 2009, 81, 1707–1714. [DOI] [PubMed] [Google Scholar]
  • 20.Alshammari QA, Pala R, Katzir N and Nauli SM, Sci. Rep, 2021, 11, 2703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan PT and Venketesan R, Nanomedicine, 2010, 6, 103–109. [DOI] [PubMed] [Google Scholar]
  • 22.Claes N, Asapu R, Blommaerts N, Verbruggen SW, Lenaerts S and Bals S, Nanoscale, 2018, 10, 9186–9191. [DOI] [PubMed] [Google Scholar]
  • 23.Ertem E, Gutt B, Zuber F, Allegri S, Le Ouay B, Mefti S, Formentin K, Stellacci F and Ren Q, ACS Appl. Mater. Interfaces, 2017, 9, 34762–34772. [DOI] [PubMed] [Google Scholar]
  • 24.Haiss W, Thanh NT, Aveyard J and Fernig DG, Anal. Chem, 2007, 79, 4215–4221. [DOI] [PubMed] [Google Scholar]
  • 25.Berbeco RI, Korideck H, Ngwa W, Kumar R, Patel J, Sridhar S, Johnson S, Price BD, Kimmelman A and Makrigiorgos GM, Radiat. Res, 2012, 178, 604–608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Asharani PV, Hande MP and Valiyaveettil S, BMC Cell Biol., 2009, 10, 65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhang YN, Poon W, Tavares AJ, McGilvray ID and Chan WCW, J. Controlled Release, 2016, 240, 332–348. [DOI] [PubMed] [Google Scholar]
  • 28.Alkilany AM and Murphy CJ, J. Nanopart. Res, 2010, 12, 2313–2333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Longmire M, Choyke PL and Kobayashi H, Nanomedicine, 2008, 3, 703–717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Dziendzikowska K, Gromadzka-Ostrowska J, Lankoff A, Oczkowski M, Krawczynska A, Chwastowska J, Sadowska-Bratek M, Chajduk E, Wojewodzka M, Dusinska M and Kruszewski M, J. Appl. Toxicol, 2012, 32, 920–928. [DOI] [PubMed] [Google Scholar]
  • 31.Tong L, Liu Y, Dolash BD, Jung Y, Slipchenko MN, Bergstrom DE and Cheng JX, Nat. Nanotechnol, 2011, 7, 56–61. [DOI] [PubMed] [Google Scholar]
  • 32.Gibbs-Flournoy EA, Bromberg PA, Hofer TP, Samet JM and Zucker RM, Part. Fibre Toxicol, 2011, 8, 2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES